517 related articles for article (PubMed ID: 23836147)
1. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.
Rosalia RA; Quakkelaar ED; Redeker A; Khan S; Camps M; Drijfhout JW; Silva AL; Jiskoot W; van Hall T; van Veelen PA; Janssen G; Franken K; Cruz LJ; Tromp A; Oostendorp J; van der Burg SH; Ossendorp F; Melief CJ
Eur J Immunol; 2013 Oct; 43(10):2554-65. PubMed ID: 23836147
[TBL] [Abstract][Full Text] [Related]
2. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
3. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes.
Kamphorst AO; Guermonprez P; Dudziak D; Nussenzweig MC
J Immunol; 2010 Sep; 185(6):3426-35. PubMed ID: 20729332
[TBL] [Abstract][Full Text] [Related]
4. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
5. FcRγ-chain ITAM signaling is critically required for cross-presentation of soluble antibody-antigen complexes by dendritic cells.
Boross P; van Montfoort N; Stapels DA; van der Poel CE; Bertens C; Meeldijk J; Jansen JH; Verbeek JS; Ossendorp F; Wubbolts R; Leusen JH
J Immunol; 2014 Dec; 193(11):5506-14. PubMed ID: 25355925
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
7. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the exogenous antigen loading of monocyte-derived dendritic cells.
Dieckmann D; Schultz ES; Ring B; Chames P; Held G; Hoogenboom HR; Schuler G
Int Immunol; 2005 May; 17(5):621-35. PubMed ID: 15824067
[TBL] [Abstract][Full Text] [Related]
9. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
Adams EW; Ratner DM; Seeberger PH; Hacohen N
Chembiochem; 2008 Jan; 9(2):294-303. PubMed ID: 18186095
[TBL] [Abstract][Full Text] [Related]
10. Stroma-dependent development of two dendritic-like cell types with distinct antigen presenting capability.
Periasamy P; O'Neill HC
Exp Hematol; 2013 Mar; 41(3):281-92. PubMed ID: 23178375
[TBL] [Abstract][Full Text] [Related]
11. Lung CD103+ dendritic cells efficiently transport influenza virus to the lymph node and load viral antigen onto MHC class I for presentation to CD8 T cells.
Ho AW; Prabhu N; Betts RJ; Ge MQ; Dai X; Hutchinson PE; Lew FC; Wong KL; Hanson BJ; Macary PA; Kemeny DM
J Immunol; 2011 Dec; 187(11):6011-21. PubMed ID: 22043017
[TBL] [Abstract][Full Text] [Related]
12. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
13. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.
Ikeuchi N; Futami J; Hosoi A; Noji S; Kurachi M; Ueha S; Fujii S; Yamada H; Matsushima K; Moriyasu F; Kakimi K
Biochem Biophys Res Commun; 2010 Feb; 392(2):217-22. PubMed ID: 20067764
[TBL] [Abstract][Full Text] [Related]
14. Comparison of lung dendritic cells and B cells in stimulating naive antigen-specific T cells.
Masten BJ; Lipscomb MF
J Immunol; 1999 Feb; 162(3):1310-7. PubMed ID: 9973384
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
16. Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway.
Canaday DH; Ziebold C; Noss EH; Chervenak KA; Harding CV; Boom WH
J Immunol; 1999 Jan; 162(1):372-9. PubMed ID: 9886409
[TBL] [Abstract][Full Text] [Related]
17. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
[TBL] [Abstract][Full Text] [Related]
18. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.
Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R
J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160
[TBL] [Abstract][Full Text] [Related]
19. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
20. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
